JYQ-164
JYQ-164 is a small molecule inhibitor of Parkinson's disease protein 7 (PARK7/DJ-1) in humans. JYQ-164 works by covalently and selectively targeting Cys106, a key residue of PARK7 (IC50=21 nM) . The high inhibitory effect of JYQ-164 on PARK7 is 5 times more potent than the previously reported inhibitor JYQ-88. JYQ-164 can be used in Parkinson's disease and cancer research[1].
Product Specifications
UNSPSC
12352005
Target
PINK1/Parkin
Type
Reference compound
Related Pathways
Autophagy; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/jyq-164.html
Purity
99.43
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C([C@H]1CN(C#N)CC1)NC(S2)=NC3=C2CN(C(C4=CC=CC(S(=O)(N5CCOCC5)=O)=C4)=O)CC3
Molecular Formula
C23H26N6O5S2
Molecular Weight
530.62
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD59 (heavy chain of Protectin) (BRA-10G), CF568 conjugate, 0.1mg/mL
TAG-72 / CA72.4 (B72.3), CF740 conjugate, 0.1mg/mL
